Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

Table 1 Patient demographics and baseline characteristics

Patient number	Age	Gender	Race	Comorbidities	Duration of CRVO (months)	Previous anti-VEGF agent	# of injections	Previous CME free interval (days)	BCVA	Central retinal thickness (µm)	Total macular volume (mm³)
001	75	F	White	HTN	12.7	Ranibizumab	10	35	20/32	303	8.89
002	86	M	White	HTN	45.5	Bevacizumab	34	35	20/50	336	8.84
003	70	M	White	DM & HTN	13.2	Ranibizumab	10	37	20/32	458	9.3
004	38	F	Hispanic	None	10.5	Ranibizumab	8	42	20/50	269	8.05
005	73	M	White	HTN	22.1	Ranibizumab	14	45	20/32	283	7.34
006	92	F	White	HTN	17.8	Ranibizumab	9	56	20/80	485	8.67
007	82	M	White	HTN	10.9	Ranibizumab	9	28	20/32	482	10.63
008	81	M	Asian	None	15.7	Ranibizumab	11	42	20/25	282	8.98
009	85	F	Hispanic	HTN	8.5	Ranibizumab	7	42	20/200	591	11.43
010	71	F	White	None	58.1	Bevacizumab	47	35	20/40	355	7.96
011	70	M	Hispanic	HTN	89.8	Bevacizumab	37	42	20/250	736	14.1
012	87	F	Hispanic	HTN	10.2	Ranibizumab	7	42	20/160	450	9.16
013	65	F	Hispanic	None	7.7	Bevacizumab	6	35	20/25	344	9.59
014	78	F	White	HTN	7.8	Ranibizumab	6	56	20/50	302	8.49
015	61	M	White	None	8.5	Ranibizumab	6	35	20/125	512	9.75
016	81	F	Hispanic	HTN	20.0	Bevacizumab	12	42	20/25	538	8.37
017	51	M	White	HTN	6.4	Bevacizumab	6	28	20/25	355	9.16
018	68	F	White	DM & HTN	31.5	Ranibizumab	18	28	20/200	772	11.7
019	55	M	Asian	None	8.5	Ranibizumab	6	35	20/32	279	8.53
020	78	M	White	HTN	30.4	Bevacizumab	31	28	20/200	559	13.56

VEGF vascular endothelial growth factor, CME cystoid macular edema, HTN hypertension, DM diabetes mellitus

ISSN: 2056-9920